Literature DB >> 10755805

Insomnia in the elderly: a review for the primary care practitioner.

S Ancoli-Israel1.   

Abstract

The elderly are known to have a high prevalence of insomnia. Causes of insomnia include: medical, psychiatric, and drug issues; circadian rhythm changes; sleep disorders; and psychosocial factors. The elderly frequently use sleeping aids. Risks associated with elderly patients' use of hypnotic drugs are attributable to concomitant comorbid conditions, use of multiple medications, altered pharmacokinetics, and increased central nervous system sensitivity to these drugs. Treatment options for insomnia include behavior modification and pharmacotherapy. The choice of hypnotics is based on matching the nature of the insomnia to the hypnotic agent. Benzodiazepine receptor agonists are common hypnotics prescribed for insomnia in the elderly. The ideal agent has rapid onset, duration of action that lasts through the night but no residual daytime effects, and no adverse effects. The longer-acting agents have been shown to result in a higher risk of falls and hip fractures in the elderly. This relationship is not apparent with short-acting agents. Zaleplon, the newest benzodiazepine receptor agonist, has the shortest half-life of available agents. Studies have demonstrated that zaleplon is effective in improving sleep latency, duration, and sleep quality in the elderly. Zaleplon does not appear to cause rebound insomnia, residual sedation, or adversely affect psychomotor function. The key for the healthcare professional is finding the appropriate treatment or treatment combination, including behavioral modification and pharmacotherapy. When hypnotics are indicated, the most appropriate short-acting agent should be considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755805

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  37 in total

1.  A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.

Authors:  Sonia Ancoli-Israel; Andrew D Krystal; W Vaughn McCall; Kendyl Schaefer; Amy Wilson; Raymond Claus; Robert Rubens; Thomas Roth
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

Review 2.  Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review.

Authors:  Hervé Allain; Danièle Bentué-Ferrer; Elisabeth Polard; Yvette Akwa; Alain Patat
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Sleep and Its Disorders in Seniors.

Authors:  Carl J Stepnowsky; Sonia Ancoli-Israel
Journal:  Sleep Med Clin       Date:  2008

Review 4.  Use of sleep-promoting medications in nursing home residents : risks versus benefits.

Authors:  David K Conn; Robert Madan
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Prescribing of psychotropics in the elderly: why is it so often inappropriate?

Authors:  Jane R Mort; Rajender R Aparasu
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Sleep Dysfunction in Alzheimer's Disease and Other Dementias.

Authors:  Susan M. McCurry; Sonia Ancoli-Israel
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

7.  Normal and abnormal sleep in the elderly.

Authors:  Jana R Cooke; Sonia Ancoli-Israel
Journal:  Handb Clin Neurol       Date:  2011

8.  Aerobic exercise improves self-reported sleep and quality of life in older adults with insomnia.

Authors:  Kathryn J Reid; Kelly Glazer Baron; Brandon Lu; Erik Naylor; Lisa Wolfe; Phyllis C Zee
Journal:  Sleep Med       Date:  2010-09-01       Impact factor: 3.492

9.  Sleep in the Elderly: Burden, Diagnosis, and Treatment.

Authors:  W Vaughn McCall
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 10.  [Drug treatment of sleep disorders in the elderly].

Authors:  M H Wiegand
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.